Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200015/S077

SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent

Edwards Lifesciences, LLC · Decision date Oct 27, 2026

MEDTECHLEDGER EXPLANATIONP200015/S077

What did the FDA approve?

On 2026-10-27, FDA recorded an approval decision (APPR) for P200015/S077, a PMA supplement submitted on the Normal 180 Day Track by Edwards Lifesciences, LLC. The supplement covers the SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent, a percutaneously delivered pulmonary valve prosthesis under product code NPV in the Cardiovascular specialty.

The recorded scope is a design change to the outflow apices of the Alterra prestent, filed under Change Design/Components/Specifications/Material. This decision modifies that component within the existing P200015 approval rather than constituting a new approval of the whole valve system. The source record includes no documents, so the specific design details, any supporting test data and the review basis are not available here; clinical implications of the apex modification remain unstated.

FDA approval order statement

Approval for a design modification to the outflow apices of the Alterra prestent.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Oct 27, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P200015/S077
Regulatory pathway
PMA supplement
Product code
NPV
Decision code
APPR
Decision date
Oct 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Pulmonary valve prosthesis percutaneously delivered.

Product code
NPV
FDA device class
f

For the original device and its historical approval scope, see PMA P200015. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200015 · Original PMA

    Edwards SAPIEN 3 Transcatheter Heart Valve System with Edwards Commander Delivery System

  2. P200015/S077 received

    Application receipt date recorded by FDA.

  3. P200015/S083 · Related supplement

    Edwards Crimper (9600LDS20, 9600LDS23, 9600LDS26, 9600LDS29)

  4. P200015/S077 · FDA decision

    Normal 180 Day Track

  5. P200015/S084 · Related supplement

    Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX)

Timeline entries are records held by MedtechLedger for P200015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200015

Explore the linked device profile

Other records with product code NPV

Product / regulatory recordCompanyPathwayDecision dateSource
Harmony TPV SystemP200046/S052
Medtronic, Inc.PMA supplementSep 30, 2026FDA
Medtronic, Inc.PMA approvalMar 26, 2021FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records